Swedish Orphan Biovitrum AB (Sobi)

Swedish Orphan Biovitrum AB, globally recognized as Sobi (STO: SOBI), is a specialized, Stockholm-based international biopharmaceutical company dedicated to rare diseases. Operating under the mission to unlock the potential of breakthrough innovations, the company transforms the everyday lives of people living with severe and often overlooked conditions. With a highly specialized workforce of roughly 1,900 employees spanning Europe, North America, the Middle East, Asia, and Australia, Sobi fundamentally addresses the massive unmet need within the rare disease landscape—a space where only 5% of known conditions currently have approved treatments.

The company's commercial and developmental pipeline is highly concentrated across three core therapeutic areas: Haematology, Immunology, and Specialty Care. Sobi is widely recognized for its robust haemophilia franchise, including the blockbuster drug Altuvoct (for Haemophilia A), as well as treatments like Doptelet and Gamifant. Moving beyond its legacy portfolio, Sobi is aggressively expanding its capabilities through strategic partnerships and late-stage pipeline development. Key upcoming growth drivers include Aspaveli (recently approved in the EU for rare kidney diseases like C3G) and Tryngolza, which recently received European Medicines Agency (EMA) validation for an indication extension to treat severe hypertriglyceridemia.

Currently guided by President and CEO Guido Oelkers, Sobi is executing a highly ambitious global growth strategy. Moving through early 2026, the company continues to ride a massive wave of commercial momentum following a stellar 2025 where it generated SEK 28.2 billion in revenue. During its February 2026 Capital Markets Day, Sobi announced an aggressive target to essentially double its revenue to SEK 55 billion by 2030. A massive pillar of this long-term strategy was cemented with the February 2026 announcement that Sobi would acquire San Diego-based Arthrosi Therapeutics in a $1.5 billion deal ($950 million upfront), adding the highly anticipated late-stage progressive gout therapy, pozdeutinurad, to its pipeline.